Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 4.1 Exhibit 4.1
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 16.1 Exhibit 16.1
- 16.2 Exhibit 16.2
- 21.1 Exhibit 21.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
OSA similar filings
- 1 Mar 23 Departure of Directors or Certain Officers
- 1 Mar 23 ProSomnus® Appoints Brian Dow as Chief Financial Officer
- 1 Feb 23 ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
- 13 Dec 22 Entry into a Material Definitive Agreement
- 8 Dec 22 Study Published in Military Medicine Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
- 6 Dec 22 Regulation FD Disclosure
Filing view
External links
Exhibit 16.2
December 12, 2022
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Prosomnus, Inc.’s statements included under Item 4.01 of its Form 8-K filed on December 12, 2022, and we agree with such statements concerning our Firm.
/s/ SingerLewak LLP